AEON
Sign in
AEON Biopharma, Inc.
Save
25.98M
Market cap
–
Current P/E
1.16x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019.
Similar securities
Based on sector and market capitalization
Report issue